Back to Journals » Vascular Health and Risk Management » Volume 6

Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy

Authors Muratore C, Baranchuk A

Published 14 July 2010 Volume 2010:6 Pages 593—601

DOI https://doi.org/10.2147/VHRM.S8355

Review by Single-blind

Peer reviewer comments 3


Claudio A Muratore1, Adrian Baranchuk2

1Department of Cardiology, Arrhythmia Service, Hospital Fernandez, Buenos Aires, Argentina; 2Department of Cardiology, Arrhythmia Service, Kingston General Hospital, Kingston, Ontario, Canada

Abstract: Chagas’ disease is an endemic disease in Latin America caused by a unicellular parasite (Trypanosoma cruzi) that affects almost 18 million people. This condition involves the heart, causing heart failure, arrhythmias, heart block, thromboembolism, stroke, and sudden death. In this article, we review the current and emerging treatment of Chagas’ cardiomyopathy focusing mostly on management of heart failure and arrhythmias. Heart failure therapeutical options including drugs, stem cells and heart transplantation are revised. Antiarrhythmic drugs, catheter ablation, and intracardiac devices are discussed as well. Finally, the evidence for a potential role of specific antiparasitic treatment for the prevention of cardiovascular disease is reviewed.

Keywords: chronic chagasic cardiomyopathy, emerging therapeutic options

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]